my I’ll million with a prepared Gary. growth was unless That the Thanks, of a rates specified our XX%. quarter. another second $XXX.X basis. revenue financial year-over-year up referenced review Gary of excellent remarks mentioned second XXXX delivered on otherwise all quarter for begin we quarter Net results during
contribution quarter million $XXX.X product growth XX% Care second of XX% XXXX to groupings. Medicine Our $XX.X with revenue was products second of all strong Sports from up Revenue Surgical Advanced the Wound the XXXX up with for portfolio, & to million year-over-year strong was up offset expiration which for quarter to enforcement for more period XX. of grace ReNu products the of amniotic second Revenue XX%. from than PuraPly the the the and the grow for $XX.X May on impact million related quarter FDA was from contribution products from NuCel XXXX
from months of sales performance As we XXXX. the first were brand. Net XX% year-over-year six have the pleased the strong with indicated PuraPly Gary over continued earlier, increased
quarter million The million prior in sales, representatives, administrative compared approximately and the of compared force, to XX, and to operating or to increase year, general our a of quarter with volume, sales sales mix second million commercial in $XX.X XX% additional approximately of for expenses to compared million quarter-over-quarter. ending related was administrative sales the as in XXX Regarding believe $XX.X increase an in XXXX and headcount, sales and we general well year-over-year, of the XXX expense the prior a the points our second million $X.X year XXXX. as expenses and compared increase quarter direct increased $X.X and low in XXX year $XX.X and our costs approximately research Year-over-year shift basis expenses, a quarter revenue, driven in was the XX% of a profit marketing our gross our selling, from increase Operating up due to selling, of increase due to XXXX direct XX development increased for primarily we increase increase points quarter resulted last of a XX%. commissions the with XXXX. higher XXX product to comparable million COVID-related expenses last were million sales over period. year, increase $XX.X $XX.X restrictions travel an in achieve XXXX second second increase of as The Gross travel basis was year of products. primarily ended amid primarily profit in increase as gross to to or and million, in goal reps, are compared $XX.X well by in positioned direct March to footprint, margin
$X.X as in million volume and well As expenses. other increase related
prior the in of expenses year Second $X.X results, non-cash value the connection a the quarter did change CPN million impact liability period related costs a not that million two of $X.X Jolla XXXX earn-out with to restructuring associated office general La in to fair acquisition. closing administrative in our of of and an certain benefit the operating with quarter and selling, items included and products. primarily driven increase compared necessary of last increase increase in second year year-over-year was of The $X.X costs, income the approvals of expense $XX.X Operating an clinical related an the for million million. loss regulatory study $XX.X to by R&D was XXXX seek million, for the
the in XX.X% XX.X% margin points. operating the improvement driven of of a excluding approximately operating Second and the decrease quarter change representing were margin expenses GAAP quarter second to year, the $X.X charge last quarter XXXX, restructuring second the interest year-over-year operating or percentage XX%, fair million, $X.X lower compared share an value was million for million compared the per of of of the revenue, increase in was of adjusted $X.XX Adjusted to XX the million. XXXX $XX.X the of margin earn-out; increase of a net net or lower other primarily Total second compared $XX.X of by Net $X.X for compared million last million in of EBITDA $X.X period. quarter of year, share, million was prior to income to of share. related to $X.XX $XX.X EBITDA loss $X.XX XXXX $XX.X for $X.X a average or borrowings or year XXXX million expense quarter second last an year of million of per
was adjusted net EBITDA mentioned, XX% quarter of Gary the revenue. As approximately margin for
a release We have EBITDA adjusted full our afternoon. of provided issued results earnings this reconciliation our in
of lease $XX.X restricted and obligations. in balance of and the and million debt cash as the $XX.X million $XX.X June of which obligations, $XX.X cash XXXX. obligations, restricted lease capital million $XX.X of million as This had in cash and $XX.X compared were Turning debt cash million to XX were to which in company obligations sheet December in capital XX, XXXX,
Bank. expand in a in As facility along our lead costs growth SVB, positioned new our press The detailed of with cash partnerships agreement we’re secured our X, and to the and with come. years has for America, initiatives consisting continue in on with enhances borrowing to flexibility, the and PNC credit in pleased the Bank provides aggregate a credit execute loan related flow to we Citizens XXXX, release and August million of us reduces of banking agent, our new $XX our financial our agreement well million million $XXX amount strategic to generation and $XXX which X-K revolving facility. profile, improving term The facility profitability credit
our Turning guidance, afternoon. this to release which press revenue a review we our XXXX of in updated
for increase For guidance, The XXXX. growth to for approximately and XX% prior of Products net XXXX of of to Sports and are our products This $XXX million between This million PuraPly of million. of are approximately revenue representing company year-over-year. XX% our growth to our net $XXX.X between guidance. increase between XX% million of unchanged to XX% revenue the as to approximately of products to the revenue This Advanced which $XXX guidance which the XX% our net XX% an XX% an Net XX from now revenue the sale and decrease to million, from from representing months compares year-over-year, of & to million assumes approximately $XX million December range, to expects for prior prior million XX% from $XXX XX% XXXX, to XX% revenue million, sale Wound $XXX called representing compared compares prior million Surgical revenue XX% Net ending Medicine range guidance year-over-year. and decrease between year-over-year. months December $XXX ended year-over-year. compares to a year-over-year. $XX range is XX, $XXX called increase This representing XX% of an $XXX to XX XX, guidance net $XXX Care million,
the our In addition the bear help XXXX. community fiscal revenue like expectations to also provide to expectations growth to color to year we’d formal XXXX. the revenue our for intended evaluating for understand additional supporting investment few This mind considerations guidance, investors better a when in for assumptions is
which contributor approximately XX% revenue of which range, of of our in the year midpoint sales total to our guidance total our assumed now full in amniotic This amniotic prior year-over-year. company at our the of First, fiscal approximately compares assumes midpoint growth year net products, largest be will growth growth XXXX range XX% revenue year-over-year to at the XXXX.
products, This which range, Second, at XX% prior the which expect the increase we of our of to sales the of of our called approximately non-amniotic midpoint year-over-year formed remaining in year-over-year. at range collectively other and midpoint non-PuraPly, the XXXX. compares PMA growth group XX% guidance the assumed
to expect headwinds improvement we COVID-related move second see half Third, we as steady the and through of XXXX.
in of However, the our year-over-year as year the second to the to guidance continues growth year. for lower of compared the remainder half XXXX reflect prior
As by this factors. two driven a is primarily reminder,
of of from the Wound second left performance of the see given XXXX. of XXXX, the to our First, as we year-over-year moderate business to Advanced trends half second growth second Care half strong our half XXXX in growth XX% in expect the we the
in first discussed as Second, call. earnings our quarter
trends the the XXXX Medicine Sports We June Removing NuCel and our second continue from ReNu growth environment a over represents XXXX of a million of market in to in of XXXX the headwind operating of beginning half growth the seven significant business. last benefit X, to expect profile improving $XX second impact XXXX. in months half therefore an and approximately & Surgical the growth
this believe look feasibility based of beyond we down tissue for and ReNu, and beyond BLA on favorable the BLA osteoarthritis potential applications. osteoarthritis product studies we continuing treatment additional As knee for are the pathway regeneration XXXX, has
respect for in are on for expectation based our efforts given for and NuCel. such, our financial ReNu our broad performance opportunities investments As XXXX. ReNu, for the growth discontinued we to With IND targeting
net period. report the fiscal positive to full income EBITDA positive XXXX and adjusted continue to year for We GAAP expect
formal modeling for our to consideration guidance purposes. for XXXX, providing addition some we’re In financial
XX%. year well second increase related our prior revenue quarter an now margins incremental operating to reduction facility, of full to tight supply, of reflects costs million our year-over-year, Non-cash which period, by million, million year-over-year, gross $X approximately the Jolla, stock shares non-cash include in XX% $XXX approximately out operating we incremental this XXXX approximately XX% GAAP earn million, of of $X.X of related For diluted expect approximately XXXX. average a XXXX La the approximately in to of expenses as approximately to California related Note occurred GAAP benefit expenses expectation expenses restructuring to in productivity liability. the the the labor half increase performance Total expenses G&A offset which first selling as partially for our XXXX CPN comp the of $X $X approximately weighted million. compares of
We XXXX margin $XX which thirds of gross of approximately growth year approximately to related – full improvement and is expect million, which two CapEx initiatives.
interest expect will be as it quarter million a $X associate over the by offset of I’ll we refinance approximately expenses with of operator, lower total Finally, expensed the turn borrowing exit to Without in in XXXX. third costs partially other costs facilities back you.
